Attendees are responsible for booking their own rooms at the New York Hilton Midtown. Room reservations made by Thursday, May 23, 2019 will be eligible for the group rate of $399.00 plus applicable taxes and fees for single or double occupancy. The negotiated group rate is based on availability and applies to reservations for Sunday, June 9, 2019 through Wednesday, June 12, 2019.
Against the backdrop of the Belgian EU Council Presidency, the Rare Diseases Forum 2024 brings together senior leaders from across patient organisations, industry and policy to address how and why innovation in tackling rare diseases can support the EU’s competitiveness agenda.
About
'The Rare Diseases Forum 2024: Securing Europe’s Competitiveness in R&D for people living with rare diseases' features keynotes and panel discussions with a focus on the EU's role in enhancing competitiveness in life sciences, fostering investment in the rare diseases sector, and examining the benefits of a competitive agenda for those with rare diseases.
The event is convened by Global Counsel on behalf of the forum partners, EURORDIS, RaDiOrg, EFPIA, Eucope, EuropaBio, Pharma.be, UCB, Novo Nordisk, Sanofi & Takeda.
Themes
In life sciences, the EU is starting to fall behind compared to other regions like the US and China, in areas including R&D expenditure, clinical trial activity and private investment. How does the EU regain its competitive edge in life sciences and what does this mean in practice?
How can the EU and member states encourage more public and private investment and collaboration into the rare diseases ecosystem?
What are the real-world impacts of an enhanced competitiveness agenda for people living with rare diseases? How does innovative R&D work alongside patient care?
Speakers: Philippe de Backer, Stefan Joris, Caroline Ven, Dr. Alexander Natz, Daria Julkowska. Moderated by Emma Eatwell.
What does EU competitiveness mean in the context of life sciences and the rare disease sector?
How can the EU’s competitiveness benefit the life sciences sector?
How will support for the single market, availability of private capital, and European R&I support people living with rare diseases?
What can EU Competitiveness do for the rare disease sector, and vice versa?
Speakers: Yann Le Cam, Prof. Elfride De Baere, Anne-Sophie Chalandon, Arjon van Hengel, Moderated by Prof. Dr. Hilde Stevens
Where are we strongest in our efforts to tackle rare diseases, and how does that relate to the EU’s competitiveness?
What do Member States need from a European Action plan for Rare Diseases?
What is the pathway for achieving an Action Plan, and what barriers can we anticipate?
Global Counsel works with companies and investors across a wide range of sectors to anticipate the ways in which politics, regulation and public policymaking create both risk and opportunity – and to develop and implement strategies to meet these challenges.
From high-level in-conversations and policy webinars, to large scale conferences, our events draw from a network of government, industry, academia and civil society to foster debate and discussion.
